Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Welcome to Pump.fun!
Pump lets anyone create coins, giving everyone equal access to buy and sell from the start. Prices can move quickly, so trade carefully.
By clicking this button, you agree to the Terms and Conditions, Privacy Policy, and certify that you are over 18 years old.
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Paired with SOL| No holders yet. | ||||||||||
ER-100 is an experimental drug candidate developed by Life Biosciences, co-founded by David Sinclair. It uses partial epigenetic reprogramming (with Yamanaka factors) to restore youthful DNA patterns and combat age-related diseases, like optic neuropathies. Pre-clinical studies show promise in animal models, with human trials planned for Q1 2026.